COVID-19 drug development based on boosting immunity
Baidyanath Dash explains the two requirements for COVID-19 drug development: killing the virus and boosting immunity.
List view / Grid view
Baidyanath Dash explains the two requirements for COVID-19 drug development: killing the virus and boosting immunity.
Anthony Finbow explains how applying microbiome-based evidence to disease modelling will enable researchers to devise more targeted treatments.
According to new research, because women have two copies of the ACE2 protein, they are less likely to suffer from severe COVID-19, unlike men who have one copy.
In this article Andrew Nyborg from Horizon Therapeutics discusses why researchers are taking a second look at gout and how they are modelling the condition, which is unique to humans.
17 December 2020 | By Living Systems Institute, University of Exeter
Watch our on-demand webinar where we explore new methods to improve data quality from high-throughput screens. You'll learn about solutions for common problems in drug-target discovery and our keynote speaker will also look at case studies where new approaches to screening have identified high-quality candidate drugs for proliferative diseases.
Researchers have shown that neutralising antibodies developed in COVID-19 patients were less potent if from those with severe or fatal disease.
According to researchers, an interaction between host microRNA and SARS-CoV-2 could be responsible for the range of disease severities.
Associate Professor Pandurangan Vijayanand from La Jolla Institute for Immunology discusses his study into the body’s immune response to SARS-CoV-2 and why this can vary.
Scientists have created a prognostic classification model which uses biomarkers to help predict an individual’s risk of developing severe COVID-19 symptoms.
The study found five key genetic differences when they compared sequences from severe COVID-19 patients to healthy individuals.
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
Two drugs, Nefiracetam and PHA 543613, were able to return neuronal signalling to near normal in organoids derived from patients with the autism spectrum disorder, Rett syndrome.
New research has provided a metabolic atlas for insights into obesity and tumours' ability to hide from the immune system.
Scientists shows targeting cholesterol or phosphatidylinositol phosphate (PIP) could be a promising strategy to combat multiple coronaviruses.
In a new report, Elsevier describes how it used text mining to reveal the top trends in pancreatic cancer research – this article outlines the findings.